Background: The aim of the study was to evaluate the performance of the 2MACE in patients
with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE …

Renal impairment confers worse prognosis in patients with atrial fibrillation (AF) but there is
scarce evidence about the influence of direct-acting oral anticoagulants in routine clinical …

Aims Although non-vitamin K antagonist oral anticoagulants are recommended for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial …

Objective: To analyze the effectiveness and safety of rivaroxaban in patients with atrial
fibrillation (AF). Methods: The clinical profile and outcomes of the EMIR study were indirectly …

Background Assessing bleeding risk during the decision-making process of starting oral
anticoagulation (OAC) therapy in atrial fibrillation (AF) patients is essential. Several bleeding …

Background This retrospective cohort study aims to compare the effectiveness and safety of
warfarin, rivaroxaban, and dabigatran in atrial fibrillation (AF) patients with different …

Background The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial …

Objective To compare the clinical benefits of rivaroxaban and warfarin in patients with non-
valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was …

Aim: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation
treated with rivaroxaban. Methods: Retrospective study in which patients treated with …

Aims To compare the effectiveness and safety of standard-dose rivaroxaban (20 mg od) and
warfarin in non-valvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2 …